New combo aims to prep patients for powerful cancer cell therapy
NCT ID NCT06788964
Summary
This study is testing whether a two-drug treatment (loncastuximab tesirine and rituximab) can safely and effectively control cancer as a 'bridge' for patients waiting to receive a standard CAR-T cell therapy. It is for adults with large B-cell lymphoma that has returned or not responded to prior treatment. The main goal is to see if this bridging approach helps patients have a better response to the subsequent CAR-T therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.